<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="28551">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02081716</url>
  </required_header>
  <id_info>
    <org_study_id>2014-0103</org_study_id>
    <nct_id>NCT02081716</nct_id>
  </id_info>
  <brief_title>Assessment of CMV-specific ELISPOT Assay for Predicting CMV Infection in Bone Marrow Transplant Recipients (ACE-BMT)</brief_title>
  <official_title>Assessment of CMV-specific ELISPOT Assay for Predicting CMV Infection in Bone Marrow Transplant Recipients (ACE-BMT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Asan Medical Center</source>
  <oversight_info>
    <authority>South Korea: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      CMV is one of the most important opportunistic infection in transplant recipients. In South
      Korea, more than 95% of adults reveal sero-positivity for CMV IgG. Until now,
      sero-positivity for CMV IgG before bone marrow organ transplantation is a laboratory test of
      choice to stratify the risk of CMV reactivation after solid organ transplantation.
      Theoretically, CMV-specific cell-mediate immune response before and after bone marrow
      transplantation will further categorize the patients into high or low risk of CMV
      development after bone marrow transplantation. The investigators thus evaluate the
      usefulness of CMV-specific ELISPOT assay in bone marrow transplant candidates to predict the
      development of CMV infection after transplantation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We will evaluate whether CMV-specific cell-mediated immune response before transplant, 1
      month, 3 months, and 6 months after transplantation will predict CMV infection after bone
      marrow transplantation.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">August 2015</completion_date>
  <primary_completion_date type="Anticipated">February 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>CMV infection</measure>
    <time_frame>6 months after transplantation</time_frame>
    <safety_issue>No</safety_issue>
    <description>CMV infection is defined as follows.
CMV viremia: CMV antigenemia or CMV quantitative PCR (+)
CMV disease: CMV syndrome or tissue-invasive CMV disease i) CMV syndrome: ① CMV viremia ② temperature &gt; 38 without other cause ③ WBC &lt; 4000, atypical lymphocyte &gt; 3%, transaminase elevation, platelet &lt; 100,000/mm ii) tissue-invasive CMV disease: evidence of CMV in histopathologic specimen (inclusion body or viral antigen in biopsy or bronchoalveolar lavage fluid)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>mortality</measure>
    <time_frame>6 months after transplantation</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Bone Marrow Transplantation</condition>
  <arm_group>
    <arm_group_label>high CMV ELISPOT results</arm_group_label>
    <description>high spot counts in ELISPOT</description>
  </arm_group>
  <arm_group>
    <arm_group_label>low CMV ELISPOT results</arm_group_label>
    <description>low spot counts in ELISPOT</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        bone marrow transplant recipients
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age 16 or more

          -  agree with written informed consent

        Exclusion Criteria:

          -  no exclusion criteria
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sung-Han Kim, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sung-Han Kim</last_name>
    <phone>82-2-3010-3305</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sung-Han Kim, MD</last_name>
      <phone>82-2-3010-3305</phone>
      <email>kimsunghanmd@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 5, 2014</lastchanged_date>
  <firstreceived_date>March 5, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Asan Medical Center</investigator_affiliation>
    <investigator_full_name>Sung-Han Kim</investigator_full_name>
    <investigator_title>Assocaite Professor</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cytomegalovirus Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
